Background Breast cancer therapies are associated with a risk of cardiac dysfunction, most
commonly defined by changes in left ventricular ejection fraction (LVEF). Recently, the …

Background: Cardiovascular disease in patients with breast cancer is of growing concern.
The longitudinal effects of commonly used therapies, including doxorubicin and …

Background There is a critical need to understand the role of biomarkers in the surveillance
of cardiac dysfunction in patients treated with cardiotoxic cancer therapy. We aimed to …

Background/Purpose This study aims to quantify the utility of monitoring LVEF, hs-cTnT, and
NT-proBNP for dynamic cardiotoxicity risk assessment in women with HER2+ early breast …

Cardiotoxicity, defined by declines in left ventricular ejection fraction (LVEF) and
symptomatic heart failure (HF), is a significant complication of commonly used treatments for …

Background We examined the longitudinal associations between changes in cardiovascular
biomarkers and cancer therapy–related cardiac dysfunction (CTRCD) in patients with breast …

Objectives: This study determined the effects of doxorubicin and/or trastuzumab on diastolic
function and the relationship between diastolic function and systolic dysfunction …

Background—Because cancer patients survive longer, the impact of cardiotoxicity
associated with the use of cancer treatments escalates. The present study investigates …

Background Cancer therapy–related cardiac dysfunction (CTRCD) is an important treatment‐
limiting toxicity for patients with human epidermal growth factor receptor 2 (HER2)–positive …

PURPOSE Cardiac dysfunction is the leading cause of mortality among 10-year breast
cancer survivors. Limited information regarding long-term risks of cardiac dysfunction after …